Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986507 (BL-B01D1) phase 1/2a combination study in advanced solid tumors with NSCLC cohorts
NL-OMON59630Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of izalontamab brengitecan in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 4 more. Started Jun 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59630.